Physician profile
Dan V Dang
NPI 1639351125
$24,005.75
in general payments reported to CMS, 2019-2025
35 companies · $12K in 2025
The $12K reported for 2025 was more than what 95% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,118 · 2020: $1,078 · 2021: $2,089 · 2022: $2,237 · 2023: $1,959 · 2024: $2,584 · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,629 · Consulting Fee: $5,811 · Travel and Lodging: $3,024 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,628.55 |
| Consulting Fee | $5,811.00 |
| Travel and Lodging | $3,023.74 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $7,647.70 | 2024-2025 | |
| Biotronik INC. | $2,540.72 | 2019-2025 | Biomonitor, Selectra, Pamira |
| Abbott Laboratories | $2,461.77 | 2019-2025 | Gallant, Jot Dx, Cardiomems |
| Medtronic, INC. | $2,074.28 | 2021-2025 | Linq II, Azure Xt Dr Mri Surescan, Reveal Linq |
| Merck Sharp & Dohme LLC | $1,432.26 | 2021-2025 | Verquvo, Capvaxive |
| Astrazeneca Pharmaceuticals Lp | $1,080.00 | 2019-2025 | Farxiga, Brilinta |
| Janssen Pharmaceuticals, INC | $880.56 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $821.43 | 2019-2025 | Eliquis, Camzyos |
| Boston Scientific Corporation | $655.76 | 2021-2025 | Watchman Flx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $627.01 | 2019-2025 | Jardiance |
| Medtronic Vascular, INC. | $602.26 | 2019-2020 | |
| Amarin Pharma, INC. | $585.66 | 2019-2021 | |
| Novo Nordisk INC | $343.49 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Novartis Pharmaceuticals Corporation | $326.52 | 2019-2025 | |
| Philips North America LLC | $326.09 | 2020-2025 | (5050) Ext Holter, Extended Holter |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $321.50 | 2019-2025 | |
| Amgen INC. | $195.26 | 2020-2025 | Repatha, Repatha |
| Akcea Therapeutics, INC. | $157.03 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $137.11 | 2023-2024 | Lifevest |
| Teva Pharmaceuticals USA, INC. | $124.99 | 2025 | Uzedy |
| Edwards Lifesciences Corporation | $118.78 | 2023-2025 | Pascal, Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Scpharmaceuticals INC. | $78.76 | 2025 | |
| Glaxosmithkline, LLC. | $72.22 | 2025 | Shingrix, Arexvy |
| Kiniksa Pharmaceuticals International, Plc | $71.00 | 2024 | Arcalyst |
| Kiniksa Pharmaceuticals, Ltd. | $48.03 | 2023 | Arcalyst |
| Astellas Pharma US INC | $45.44 | 2019 | |
| Shockwave Medical, INC | $38.98 | 2025 | |
| Blueprint Medicines Corporation | $32.03 | 2021 | |
| Alnylam Pharmaceuticals INC. | $25.90 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $25.66 | 2024 | |
| Sanofi-Aventis U.S. LLC | $24.11 | 2019 | |
| Esperion Therapeutics, INC. | $24.01 | 2020 | |
| Irhythm Technologies, INC. | $23.79 | 2019 | |
| Gilead Sciences, INC. | $22.46 | 2019 | |
| Medicomp INC | $13.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dan Dang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.